Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 18/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875468 | 0.82 | MAOB (0.53) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL16047504 | 0.70 | MAOB (0.60) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL5875376 | 0.69 | PARP14 (0.48) | MAOBGRM5MAOANR4A2 | |
| SCHEMBL27521276 | 0.66 | MAOB (0.77) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL13463304 | 0.66 | CYP3A4 (0.56) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL20377567 | 0.65 | MAOB (0.59) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL16047468 | 0.65 | MAOB (0.68) | MAOBGRM5MAOANR4A2PARP10 | |
| SCHEMBL31094217 | 0.65 | MAOB (0.57) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL20377549 | 0.65 | NR4A2 (0.65) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL12735859 | 0.65 | MAOB (0.50) | MAOBMAOANR4A2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572666-B1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-7087612-B2 | Amine oxidase inhibitor; therapy for Alzheimer's diseases, Parkinson's disease | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1572666-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | US | disclosed |
| WO-2004054985-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | MAOB, MAOA, COMT | MAOB 1/4885GRM5 1819/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.